Cancer Immunotherapy Flashcards

1
Q

What are teh 4 major methods of immunotherapy?

A

stimulate/block components of hte immune system; inject tumour specific immune cells; genetically engineer immmune cells to recognise tumour; deplete immune subsets- Tregs ; MDSC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the only 2 cytokine therapies approved?

A

IFNa and IL-2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What cancers is IL-2 used against?

A

metastatic melanoma nad renal cell carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the function of IL-2?

A

activation and expansion of CD4 and CD8 T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

When is IFNa used in treating cancers?

A

as an adjuvant therapy of stage III melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the function of type I IFNs?

A

induce expression of MHC-I; mediates maturation of DCs; activates CTLs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the efficacy of cytokine therapy?

A

recent meta-analysis found significant increases in disease free survival and overall survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Why would IFNa therapy be thought to be particularly good?

A

many cancers switch off this expression in order to evade the immune repsonse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What makes developing a therapeutic cancer vaccination difficult?

A

need to find a protein/peptide that specifically expressed in cancers and not normal cells, however most tumour associated antigens are self-antigens and therefore there is tolerance to them; even if generate good responses, cancers create immunosuppressive microenvironment which is notovercome by the vaccine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What makes peptide vaccination difficult?

A

class I MHC restriction limits relevance of individual peptides to certain HLA types; short peptides may bind directly to MHC on non-professional APCs inducing tolerance; rapidly degraded by proteases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the overall response rate for protein/peptide vaccination?

A

3-5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How many the efficacy of protein/peptide vaccines be improved?

A

combinding with otehr treatments e.g checkpoints inhibitors or once finished cancer treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the most common carcinogenic HPV types?

A

types 16 and 18

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the result of HPV infection?

A

causes cellular transformation and leads to changes to a less differentiated cell type

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What proteins does HPV cause the production of ?

A

E6 and E7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the function of E6?

A

binds and inactivates host p53 which is essential in apoptosis in DNA damaged cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the function of E7?

A

promotes host and viral DNA replication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the two forms of monoclonal antibody?

A

naked and conjugated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are naked mAbs?

A

bind to antigens on tumour cell, other cells in tumour environment or free proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are conjugated mAbs?

A

act as homing devices to deliver radioactive particle, toxin or chemo drug to tumours

21
Q

What is the double-edged sword of the specificity of monoclonals ?

A

reduction in SE profile but antigen identification is important and may differ between cancers

22
Q

What are the 4 methods by which mAbs work?

A

block receptor mediated signalling for tumour cell survival and/or growth; mark the tumour cell fro immune mediated destruction; delivering targeted drugs; blocking immunosuppression pathways

23
Q

What happens when a ligand binds to a growth factor receptor?

A

triggers a dimerisation event and activation of a signalling casacde leading to cellular proliferation and resistance to cytotoxic agents

24
Q

How does mAb block signalling?

A

can occur by blocking the dimerisation event or by interfering with ligand binding

25
What is herceptin used for?
to treat HER2 positive tumours in breast and gastric cancers
26
What are the mechanisms of action of herceptin?
triggers HER2 internalisation and degradation; marks cells for NK cell attack and inhibits MAPK and PI3K/Akt pathways
27
What is a major problem with herceptin?
resistnace develops in virtually all patients
28
What are the mechanisms of cancer resistance?
altered target expression ( as cancer progresses de-differentiates); altered target (mutation in receptr); overexpression of other receptors and signalling by alternative pathways- bypassing blockade
29
What are hte 2 benefits of ADCC with mAbs?
causes direct killing or tumour cell whilst creating cell debris that can be presented to other immune cells to stimulate immune response against more tumour cells
30
What is rituximab used to treat in cancer?
CLL and non-hodgkins
31
What is the response rate to rituximab?
48%
32
What are the methods of tumour killingwith rituximab?
complement mediated cytotoxicitiy; direct lysis; FcyR/CR-mediated opsonic phagocytosis or ADCC
33
Give an example of an antibody-drug conjugate?
Brentuximab vedotin which targets CD30 antigen on lymphocytes attached to a chemotherapy drug
34
How does antibody-directed enzyme prodrug therapy work?
mAb enzyme conjugate bind to tumour cell-surface antigen and prodrug adminstered binds to mAb-enzyme conjugate on the tumour cell surface releasing prodrug at highest concentrations in the tumour microenvironment
35
What is the problem with autologous tumour cell vaccine?
low cell numbers and not very efficacious
36
How does autologous tumour cell vacine work?
remove tumour cells at surgery, treat with radiation to increase immunogenicity and then give back to patietn
37
How have tumour infiltrating lymphocytes been used in cancer immunotherapy?
select and expand TILs from biopsies which have not been very repsonsive and is very expensive and labour intensive
38
What are the 2 methods of engineering T cells?
genetically insert a TCR specific for a tumour antigen or insert genes encoding a tumour specific chimeric antigen receptor
39
What is the benefit of CAR T cells?
they tagret surface antigens in an MHC independent fashion
40
What is the T body in CAR T cells?
essneitally an antibody with an intracellular signalling domain
41
Where has there been evidence of CAR persistence?
in immunohistochemistry and PCR of bone marrow
42
What is the problem with CAR T cells?
can cause cytokine storms and there is no knowledge of the long-term effects
43
When have CAR T cells been used successfully?
in treating chronic lymphocytic leukaemia and ALL
44
What solid tumour have CAR T cells been shown to be effective in mice?
ovarian tumours
45
What type of antigen do yd T cells recognise?
phosphoantigen
46
What are the benefits of using yd T cells?
very effective at killing tumour cells; don't rely on MHC
47
What is the most common subpopulation of yd T cells in humans?
Vy9Vd2 T cells
48
Waht is hte function of combination therapies?
to increase immune recognition of cancer cells